On October 1, 2009, the Food and Drug Administration (FDA) published a proposed rule clarifying postmarketing safety reporting requirements that apply when regulated products (drugs, devices, and biological products) are combined to create a combination product. The FDA is accepting comments on the proposal until December 30, 2009.